menu
menu
Immuno-oncology
This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in understanding and addressing the challenges in evaluation of PD-L1 expression by immunohistochemistry.
This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in understanding advances in I-O biomarkers, in particular, PD-L1, MSI, and TMB. This activity focuses on evaluation methods and clinical significance of each of these biomarkers.
This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in understanding optimizing the use and evaluation of biomarkers such as PD- L1, MSI, and TMB. Potential pitfalls in biomarker utilization and strategies to overcome challenges.
This activity is supported by an independent educational grant from Bristol Myers Squibb.
This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team stay up to date on the clinical implications of PD-L1 testing.
This course addresses the role of biomarker testing in resectable NSCLC, including PD-L1, EGFR, and ALK. You will also learn about the evaluation of posttreatment lung cancer resection specimens.
In this course, you will learn about the complexity of advanced NSCLC, including making accurate diagnosis on small samples, identifying actionable mutations, and determining PD-L1 expression levels.
In this course, you will learn about biomarkers for the diagnosis, prognosis, and prediction of therapeutic response in patients with advanced melanoma.
This course addresses measurement and scoring of pathologic response in resectable melanoma, best practices for specimen collection and handling, and immunotherapy-related pathologic response scoring systems to assess pathologic response.
This course will provide you with an increased understanding of PD-L1 testing considerations.
This course will provide you with an increased understanding of health disparities impacting the ability of Black persons and other persons of color with cancer to access I-O therapies.
This course is designed to help you learn how PD-L1 testing and interpretation is performed using CPS.
In this course, you will learn key considerations when establishing a PD-L1 LDT and what is involved with validation and scoring different types of cancers.
This course will help you learn how PD-L1 testing and interpretation is performed in patients with advanced triple negative breast cancer (TNBC), including key considerations when assessing pathological complete response (pCR) following neoadjuvant therapy.